Van ECK Associates Corp Reduces Position in Novo Nordisk A/S $NVO

Van ECK Associates Corp decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 35.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,045,885 shares of the company’s stock after selling 575,596 shares during the period. Van ECK Associates Corp’s holdings in Novo Nordisk A/S were worth $50,140,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $25,000. Transamerica Financial Advisors LLC boosted its stake in Novo Nordisk A/S by 201.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after purchasing an additional 403 shares during the period. Johnson Financial Group Inc. grew its position in Novo Nordisk A/S by 128.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after purchasing an additional 384 shares during the last quarter. Scarborough Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $26,000. Finally, Kingdom Financial Group LLC. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $41,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. BMO Capital Markets reissued a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research note on Wednesday, August 12th. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Four equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $64.94.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Trading Down 1.4%

Shares of Novo Nordisk A/S stock opened at $45.59 on Friday. The firm has a market cap of $203.56 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 4.11 and a beta of 0.76. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company’s 50-day simple moving average is $48.03 and its 200-day simple moving average is $43.90. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The firm had revenue of $11.98 billion during the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 20.05%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.